Th/Tr淋巴细胞比值评估乳腺癌患者抗肿瘤免疫状态被引量：1

Assessment of Th/Tr lymphocyte ratio on the anticancer immune status in breast cancer patients

导出

摘要目的:探讨用Th/Tr淋巴细胞比值评估乳腺癌患者的抗肿瘤免疫状态。方法:采用流式细胞术检测53例不同分期的乳腺癌患者化疗前外周血中CD4+Th细胞、CD4+CD25+Tr细胞水平,计算Th/Tr比值,并与30例健康志愿者进行比较。结果:有转移与无转移的乳腺癌患者Tr细胞绝对值差异无统计学意义(103±75vs 109±70,P=0.722)。有转移的乳腺癌患者Th/Tr淋巴细胞比值小于无转移者(3.83±1.37 vs 6.11±2.93,P<0.001),无转移患者小于健康志愿者(6.11±2.93 vs 11.24±1.84,P<0.001)。结论:Th/Tr比值对乳腺癌患者抗肿瘤免疫状态的评估优于Tr细胞计数,Th/Tr比值在乳腺癌患者尤其是有转移的乳腺癌患者中显著降低,其水平变化可作为评估乳腺癌患者免疫状态的有效指标。 Objective：To explore the use of Th/Tr lymphocyte ratio to assess the anticancer immune status in breast cancer patients.Methods： The number of CD4^＋ helper T cells and CD4^＋CD25^＋regulatory T cells in peripheral blood of 53 patients with breast cancer and 30 healthy donors was determined by flow cytometry,the Th/Tr lymphocyte ratio was then computed.Results： The difference of Tr cells absolute mean number between breast cancer patients with and without metastasis was not statistically significant（103±75 vs 109±70,P=0.722）.The Th/Tr lymphocyte ratio of metastatic patients was lower than that of non-metastatic patients（3.83±1.37 vs 6.11±2.93,P〈0.001）,and the ratio of non-metastatic patients was lower than that of healthy donors（6.11±2.93 vs 11.24±1.84,P〈0.001）.Conclusion： The Th/Tr lymphocyte ratio is better than cell number in assessment of the anticancer immune status in breast cancer patients.The decrease of the Th/Tr lymphocyte ratio may be related to immunosuppression and tumor progression in breast cancer patients.The change of Th/Tr lymphocyte ratio will provide a clinical index for judging the immune status.

作者刘辉杨波吴亮亮孙婷婷焦顺昌

机构地区解放军总医院肿瘤内科

出处《现代肿瘤医学》 CAS 2010年第4期689-691,共3页 Journal of Modern Oncology

基金军队十一五攻关课题(编号:06G106)

关键词乳腺癌 CD4+CD25+调节性T细胞 Th/Tr比值流式细胞术 breast cancer CD4^＋CD25^＋regulatory T cells Th/Tr lymphocyte ratio flow cytometry

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Okita R,Saeki T,Takashima S,et al.CD4^+CD25^+regulatory T cells in the peripheral blood of patients with breast cancer and non small cell lung cancer[J].Oncol Rep,2005,14(5):1269-1273.
2Antony PA,Restito NP.CD4^+CD25^+T-regulatory cells,immunotherapy of cancer and interleukin-2[J].J Immunother,2005,28(2):120-128.
3Sasada T,Kimura M,Yoshida Y,et al.CD4^+CD25^+ regulatory T-cells in patients with gastrointestinal malignancies:possible involvement of regulatory T-cells in disease progression[J].Cancer,2003,98(5):1089-1093.
4Lissoni P,Brivio F,Fumagalli L,et al.Enhancement of the efficacy of chemotherpy with oxaliplatin plus 5-fluorouracil by pre-treatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy[J].In Vivo,2005,19(6):1077-1080.
5Stuhler G,Walden P.朱立平,张伟,译.癌症免疫治疗[M].北京:化学工业出版社,2004:85.
6张国庆,焦顺昌,林星石,魏秀芳.恶性肿瘤患者外周血淋巴细胞体外扩增后亚群的变化[J].军医进修学院学报,2008,29(3):184-186. 被引量：13
7李欣,崔永生,王炎,郑晓辉,李一.CD4^+ CD25^+调节性T细胞在Lewis肺癌移植鼠中的检测及临床意义[J].现代肿瘤医学,2007,15(4):454-457. 被引量：10
8Kunutso KL,Disis ML,Salazar LG.CD4 regulatory T-cells in human cancer pathogenesis[J].Cancer Immunol Immunother,2007,56(3):2471-2485.
9Cesana GC,DeRaffaele G,Cohen S,et al.Characterization of CD4^+CD25^+ regulatory T-cells in patients treated with high-dose interkleukin-2 for metastatic melanoma or renal cell carcinoma[J].J Clin Oncol,2006,24(7):1169-1177.

二级参考文献13

1吴长有,刘杰,杨滨燕,Mario Roedere.人外周血NK细胞亚群、表型和生物学特征[J].中国免疫学杂志,2005,21(7):483-486. 被引量：34
2张利宁.调节性T细胞与肿瘤[J].中国肿瘤生物治疗杂志,2007,14(3):201-205. 被引量：8
3Morgan ME,van Bilsen JH,Bakker AM,et al.Expression of FOXP3 mRNA is not confined to CD4^+ CD25^+ T regulatory cells in humans[J].Hum Immunol,2005,66 (1):13 ～20.
4Brunkow ME,Jeffery EW,Hjerrild KA,et al.Disruption of anew forkhead/winged-helix protein,scurfin,results in the fatal lymphoproliferative disorder of the scurfy mouse[J].Nat Genet,2001,27(1):68 ～73.
5Fontenot JD,Gavin MA,Rudensky AY,et al.Foxp3 procams the development and function of CD4^+ CD25^+ regulatory T cells[J].Nat Immunol,2003,4:330 ～ 336.
6Gallimore A,Aguchi S.Regulation of tumor of immunity by CD25^+ T cells[J].Immunol,2002,107:5 ～ 9.
7Suciu-Foca N,Manavalan JS,Scotto L,et al.Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells:review[J].Int Immunopharmacol,2005,5 (1):7 ～11.
8Hoffmant DM,Gitlitz BJ,Belldegrun A,et al.Adoptive cellular therapy[J].Semin Oncol,2000,27(2):221-233.
9Linn YC,Lau LC,Hui KM.Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts[J].Br J Haematol,2002,116(1):78-86.
10Introna M,Franceschetti M,Ciocca A,et al.Rapid and massive expansion of cord blood-derived cytokine-induced killer cells:an innovative proposal for the treatment of leukemia relapse after cord blood transplantation[J].Bone Marrow Transplant,2006,38(9):621-627.